Device Trial Radar · NCT04185961
Pilot Study to Determine the Optimal Negative Pressure for Non-invasive Breast Augmentation in Women
Last checked: Nov 20, 2026Latest source record: May 20, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
16
Actual
Start
Jan 6, 2020
Primary completion
Mar 30, 2020
Study completion Apr 6, 2020
Sponsor
- Lead sponsor
- Seoul National University HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Dec 4, 2019
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated device
- No
- Who can join
- Female only, from 20 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Aim is to investigate optimum pressure and evaluate safety and effectiveness of EVERA-RAPHA for breast augmentation
Conditions
- Breast Hypoplasia
Interventions
EVERA-RAPHA with 60mmHGDevice
Apply EVERA-RAPHA with 60mmHG for 4weeks
EVERA-RAPHA with 100mmHGDevice
Apply EVERA-RAPHA with 100mmHG for 4weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- change in the breast volume between before and after 4 weeks in test group 1 and test group 2 respectively.Time frame: Baseline and after 4 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Seoul National Univ. Bundang Hospital
Seongnam-si, Bundang,Gyeonggi-do, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.